Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood protein may help doctors spot cause of lung fluid

NCT ID NCT07338227

Diagnosis Sponsor: Beni-Suef University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether measuring a protein called Clara cell protein 16 (CC16) in the blood can help doctors tell the difference between two types of lung fluid buildup: one caused by heart problems and another caused by lung injury. Researchers measured CC16 levels in 100 ICU patients who needed a breathing tube. The goal was to see if this simple test could guide faster, more accurate treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Clara cell protein 16 (CC16) measurement
What this could lead to
If CC16 proves reliable, it could give doctors a simple blood test to quickly identify the cause of lung fluid buildup, leading to faster, more targeted treatment.
What could go wrong
This is a small, completed validation study. The test may not be accurate enough for routine use, and results need confirmation in larger, diverse patient groups before it becomes standard practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Jan 2023

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study employed a prospective observational design to evaluate 100 patients receiving intubation, mechanical ventilation, and admission to the critical care department at Beni-Suef General Hospital between January 2023 and January 2024 for cardiogenic or non-cardiogenic pulmonary edema. Ethical approval was obtained from Cairo University's Faculty of Medicine.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18 years or older. * Both sexes. * Patients requiring intensive care unit (ICU) admission and intubation. * Inclusion criteria followed the American-European Consensus Conference diagnostic guidelines for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): acute respiratory failure onset, bilateral infiltrates on chest radiography, a PaO2/FiO2 ratio below 300 for ALI or 200 for ARDS and no evidence of left atrial hypertension Exclusion Criteria: * Critically ill but not intubated. * Had a mixed cause of pulmonary edema like pneumonia with heart failure.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiogenic pulmonary edema are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lung injury acute respiratory distress syndrome pulmonary edema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiogenic pulmonary edema Clara cell protein Diagnostic biomarker Differentiation Non-cardiogenic pulmonary edema

Contacts and locations

Locations

  • Beni Suef University

    Banī Suwayf, Beni Suweif Governorate, 62511, Egypt